Reducing baseline toxicity in fishery product-related sediments from land to sea: Region-specific solutions are required.

Eastern China is a major producer of fishery products (including inland aquaculture, coastal mariculture, and coastal fishing products). The quality of the products is affected by hydrophobic organic contaminants (HOCs) in the sediments. Based on in-vitro luminescent bacterial assay, the baseline toxicity (BEQBio) of 56 common HOCs were assessed in the present study. Specifically, the BEQBio of sediments declined from land (31-400 mg/kg) to sea (9.1-270 mg/kg). However, the toxicity contribution explained by the HOCs increased gradually from land (0.70 %) to sea (10 %) using Iceberg Modeling. In the inland pond, current use HOCs (pyrethroid pesticide (PEs), organic tin (OTCs), and antibiotic) exhibited considerable concentrations, although their toxicity contribution was very small (0.076 %), thus more regulations on the use of HOCs should be proposed and further screening is needed to confirm the major toxicants. In coastal mariculture area, the toxicity contribution of current use HOCs further declined (0.010 %), whereas environmental background HOCs, such as polycyclic aromatic hydrocarbons (PAHs), became increasingly significant, with the contribution ratio increasing from 0.37 % to 2.4 %. To minimize the negative impacts of PAHs, optimization of energy structure in transportation and coastal industry is required. In the coastal fishing area, the phased-out persistent organic pollutants (POPs) remained a major concern, in terms of both concentration and toxicity contribution. The phased-out POPs explained 7.0 % of the toxic effects of the sediments from the coastal fishing area, due to historical residue, industrial emissions, and their high toxicities. For this reason, it is critical to improve the relevant emission regulations and standards, so as to eventually reduce the unintentional discharges of POPs.

The effective components of Chinese medicine combined with scaffold materials promote bone tissue regeneration / 中国组织工程研究

BACKGROUND:With the proven ability of traditional Chinese medicine such as icariin and berberine to promote bone regeneration by regulating various mechanisms and targets,researchers have combined active ingredients of traditional Chinese medicine with bone tissue engineering and found that they have unique advantages in treating bone defects. OBJECTIVE:Starting from the active ingredients of traditional Chinese medicines that promote bone formation,to screen cases of their effective combination with different drug-carrying scaffold materials,and summarize the active ingredients of traditional Chinese medicines that have the potential to be applied to bone tissue engineering. METHODS:CNKI,WanFang,PubMed,and Web of Science were searched for relevant literature published from 2000 to 2023,using the keywords of"bone tissue engineering,bone tissue-engineered scaffold materials,bone defect,bone repair,bone regeneration,traditional Chinese medicine"in Chinese and English.According to the inclusion and exclusion criteria,87 papers were finally included for review. RESULTS AND CONCLUSION:There are various kinds of active ingredients of traditional Chinese medicine to promote bone regeneration,mainly including flavonoids,non-flavonoid polyphenols,alkaloids,glycosides.These active ingredients have anti-inflammatory and analgesic effects,promote osteoblasts,inhibit osteoclasts and promote early angiogenesis.The combination of active ingredients of traditional Chinese medicine with bone tissue engineering is effective in anti-inflammation,accelerating collagen and bone formation,and promoting the expression of osteogenic genes,which provides a theoretical basis for the application of traditional Chinese medicine in bone tissue regeneration,and at the same time provides a new idea for the repair of bone defects.

Research of aromatase inhibitor-associated arthralgia / 国际肿瘤学杂志

Aromataseinhibitors(AI)aretheleadingcarefortheadjuvanttreatmentofhormone responsive carcinoma of the breast as demonstrated in a number of large international phase III randomised tri-als.Aromatase inhibitor-associated arthralgia (AIA )was a somewhat unexpected side effect of this class of agents and has proven to be potentially problematic in clinical practice.The pathogenesis of AIA is not very clear currently,with the cause of most research focusing on estrogen deprivation,immune abnormalities,tenosy-novial changes and joint effusions.It is extremely urgent that we evaluate this syndrome and select appropriate therapeutic strategies to reduce the incidence of AIA,thereby improving breast cancer-related outcomes.